GET DAILY SIGNALSWhy Is Astrana Health (ASTH) Stock Down -15.41% Today?
Key Takeaways
- ASTH shares plunged roughly 15.41% to $33.00, down from the prior session's close of $39.01.
- The primary catalyst was a third-quarter earnings miss: adjusted EPS of $0.71 came in well short of the roughly $0.88 consensus, and GAAP EPS of $0.26 missed the $0.48 estimate.
- Guidance weighed on sentiment, with fourth-quarter revenue guided to a midpoint below the third quarter and full-year revenue guidance narrowed.
- A newly disclosed cybersecurity incident—now deemed material—and flagged internal control weaknesses compounded the sell-off.
- The decline extends recent pressure on the value-based care name following a short-seller report and investor law-firm investigations.
- Traders are now watching management's cybersecurity updates, Medicaid membership trends, and whether the earnings miss triggers further analyst revisions.
- For deeper data on this move, explore Price Targets, Earnings, and Forecast pages for ASTH.
- To see how AI-driven strategies are navigating volatile names like this one, visit Trending AI Robots.
Opening Summary
Astrana Health, Inc. (ASTH), a physician-centric, technology-powered healthcare management company based in Alhambra, California, saw its stock tumble roughly 15.41% on Thursday, closing the session's active trading near $33.00 versus a prior close of $39.01. The sharp decline marked a decisive downside reaction to the company's third-quarter 2026 results, which revealed a meaningful earnings miss, cautious near-term guidance, and new disclosures around a material cybersecurity incident and internal control weaknesses.
Earnings Miss and Soft Guidance
The most immediate trigger for the sell-off was the company's third-quarter report. Astrana Health posted record revenue of approximately $1.02 billion, up 7% year over year, and adjusted EBITDA of roughly $77.2 million, up 13%. However, the headline profitability figures disappointed investors: adjusted diluted EPS of $0.71 fell short of the approximately $0.88 consensus, while GAAP EPS of $0.26 came in far below the roughly $0.48 that analysts had modeled. The earnings-driven move reflected concerns that, despite strong top-line growth, profitability per share is not expanding as quickly as the Street had anticipated.
Guidance added further pressure. Management issued fourth-quarter revenue guidance in the range of roughly $939 million to $1.04 billion—a midpoint below the third quarter's level—and narrowed its full-year revenue outlook to approximately $3.9 billion to $4.0 billion. The sequential step-down in the revenue guide signaled to investors that growth momentum may be moderating heading into 2027, particularly as the company manages an expected mid-single-digit to double-digit decline in Medicaid membership.
Cybersecurity Incident and Internal Controls
Beyond the headline numbers, the company disclosed that a cybersecurity incident involving unauthorized data access has now been determined to be material, though management stated it does not expect a material financial impact. On the earnings call, executives acknowledged an ongoing investigation—including involvement with law enforcement—and emphasized a focus on protecting patients, providers, and payer partners. Separately, commentary pointed to internal control deficiencies that added a layer of governance uncertainty. Together, these disclosures reinforced a cautious stance among investors already on edge about operational and reputational risk.
Broader Sentiment and Recent Overhang
The sell-off also extends an existing overhang on the stock. In September, ASTH fell sharply after GlassHouse Research published a short report targeting the company, and several investor-rights law firms subsequently announced investigations into the company. While analyst ratings have generally remained constructive—with a consensus leaning toward Strong Buy and average price targets well above the current share price—the combination of a short-seller campaign, regulatory scrutiny, and now an earnings miss has kept risk appetite subdued. The market reaction underscores how quickly sentiment can shift for high-valuation, risk-bearing healthcare names when execution questions emerge.
Market Context and Trading Activity
Trading volume was elevated as investors digested the results, consistent with a catalyst-driven repricing rather than a gradual drift lower. The move reflects company-specific factors more than a broad sector sell-off, though value-based care and managed-care peers have faced their own valuation and regulatory pressures in recent months. The decline pushed ASTH through key near-term support levels established during the stock's prior consolidation, leaving the shares trading well below their 52-week highs and placing renewed focus on technical levels and analyst price targets as potential guideposts.
What Comes Next for Astrana Health
Looking ahead, investors will be watching for further updates on the cybersecurity investigation and any associated remediation costs or liabilities. Medicaid membership trends and the company's ability to hold or grow margins under risk-bearing contracts will be central to the next several quarters, as will the integration of recently acquired assets. The narrowed full-year guidance leaves limited room for error, and any additional analyst estimate revisions could influence near-term price action. Risks include continued policy and reimbursement uncertainty in government healthcare programs, execution challenges tied to the company's expansion strategy, and lingering fallout from the short-seller report and related investigations.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that have demonstrated the strongest performance under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. Only the top performers are featured in this section, giving traders a way to explore systematic, data-driven approaches to volatile stocks like ASTH. Consider browsing the page to see how AI strategies are adapting to today's market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ASTH in downward trend: price may drop because broke its higher Bollinger Band on November 04, 2026
ASTH broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 50 similar instances where the stock broke above the upper band. In 42 of the 50 cases the stock fell afterwards. This puts the odds of success at 84%.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASTH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 54 cases where ASTH's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on ASTH as a result. In 68 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for ASTH just turned positive on November 04, 2026. Looking at past instances where ASTH's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
ASTH moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for ASTH crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +4.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASTH advanced for three days, in 241 of 317 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 119 of 195 cases where ASTH Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 61%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ASTH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 76 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 81 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.099) is normal, around the industry mean (203.977). P/E Ratio (42.878) is within average values for comparable stocks, (20.904). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.097) among similar stocks. P/S Ratio (0.485) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 83 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASTH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 82, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement